Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen 518118, China ...

Pfizer has a follow-up CDK 2/4/6 inhibitor called PF-06873600 in early-stage human testing for breast cancer. Around two-thirds of all breast cancer cases fall into the HR+/HER2- category ...

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone receptor-positive and HER2-negative. Currently, there are three CDK4/6 inhibitors approved ...

There is a huge need to identify patients who may or may not benefit from adding CDK4/6 inhibitors at the time of metastatic diagnosis to guide escalation and de-escalation strategies in advance ...

The first of these, CDK 2/4/6 inhibitor NUV-422, is due to start a phase 1/2 trial in gliomas, including a form called glioblastoma multiforme (GBM) with very few treatment options, in the first q ...

Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus endocrine therapy rather than ...

While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, HER2-negative metastatic breast cancer, Pedram Razavi ...

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in HR-positive, HER2-negative metastatic breast cancer. In a retrospective study ...

A new analysis of the SONIA trial found that the timing of CDK4/6 inhibitor use in patients with advanced hormone receptor-positive, HER2-negative breast cancer did not affect their health-related ...